Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Bonum Therapeutics | 2022 | Series A | $93.0M | Seattle |
| Tricida | 2022 | Post Ipo Debt | $125.0M | Menlo Park |
| RayzeBio | 2022 | Series D | $160.0M | San Diego |
| Atekka | 2022 | Series Unknown | $4.9M | Paris |
| Inspirna | 2022 | Series D | $55.1M | New York |
| Cerebral Therapeutics | 2022 | Series C | $40.0M | Aurora |
| Visirna Therapeutics | 2022 | Seed | $60.0M | Shanghai |
| Aerobiotix | 2022 | Debt Financing | $10.0M | Miamisburg |
| Ablaze Pharmaceuticals | 2021 | Series A | $75.0M | Jingan |
| Platelet BioGenesis | 2021 | Series B | $75.5M | Watertown |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 76 | Bonum Therapeutics | Series A | $93.0M | Seattle, United States |
| 77 | Tricida | Post Ipo Debt | $125.0M | Menlo Park, United States |
| 78 | RayzeBio | Series D | $160.0M | San Diego, United States |
| 79 | Atekka | Series Unknown | $4.9M | Paris, France |
| 80 | Inspirna | Series D | $55.1M | New York, United States |
| 81 | Cerebral Therapeutics | Series C | $40.0M | Aurora, United States |
| 82 | Visirna Therapeutics | Seed | $60.0M | Shanghai, China |
| 83 | Aerobiotix | Debt Financing | $10.0M | Miamisburg, United States |
| 84 | Ablaze Pharmaceuticals | Series A | $75.0M | Jingan, China |
| 85 | Platelet BioGenesis | Series B | $75.5M | Watertown, United States |
Bonum Therapeutics creates a technology platform to treat a wide range of diseases.
Tricida operates in the healthcare industry focusing on pharmaceutical business.
RayzeBio is a pharmaceuticals company that develops targeted radiopharmaceutical drugs for cancer.
Atekka is a new generation agricultural insurance company.
Inspirna is a biotechnology company developing drugs for the treatment of cancer.
Cerebral Therapeutics is a clinical-stage pharmaceutical company.
Visirna Therapeutics to develop and commercialize RNAi therapeutics targeting cardiovascular and metabolic diseases.
Aerobiotix is a privately held company specializing in the development and manufacture of proprietary environmental management devices.
Ablaze Pharmaceuticals is a clinical-stage pharmaceutical company.
Platelet Biogenesis is an allogeneic cell therapy company that focuses on platelet biology.
A private biopharmaceutical company .
Bolt Biotherapeutics is a biotechnology company that develops a platform for cancer immunotherapy.
Telomere Therapeutics is a University of Barcelona spinoff developing telomerase gene therapy to treat pulmonary fibrosis
Fortis Therapeutics is an immuno-oncology biotech focused on developing new antibody drug conjugate therapies against CD46.
MiiMOSA operates a crowd funding platform dedicated to agriculture and food.
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product.
InnoCare is a Chinese biopharmaceutical company that develops treatment for cancer and autoimmune diseases.
Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders.
Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.
Kira Pharmaceuticals is a Biotechnology Research Company.
Homology Medicines is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases.
PatientPop is the only complete practice growth solution that empowers healthcare providers to thrive in the digital age.
Citrine Medicine is a rare disease-focused pharmaceutical firm.
Telum Therapeutics is a biotechnology company.
Tranquis Therapeutics is focused on the discovery and development of therapies to treat neurodegenerative and aging-related diseases.
Vivo Capital has invested in 105 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Vivo Capital's top investment sectors include Biotechnology, Health Care, Pharmaceutical, Medical, Therapeutics. The firm invests across 23 different industry categories.
Among tracked funding rounds, RayzeBio received $160.0M in a Series D round. Vivo Capital's total known invested capital is $5.6B.
Vivo Capital's average investment size is $78.6M across its portfolio of 105 companies.
Recent Vivo Capital portfolio additions include Bonum Therapeutics, Tricida, RayzeBio, Atekka, Inspirna. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors